Hit by FDA red flags, cited for misleading investors and battered by a thumbs-down from experts, it’s been one terrible week for Trevena

Hit by FDA red flags, cited for misleading investors and battered by a thumbs-down from experts, it’s been one terrible week for Trevena

Source: 
Endpoints
News Tags: 
snippet: 

Trevena’s fall from grace — and into penny stock territory — gathered steam on Thursday evening as a slight majority of outside experts at the FDA turned thumbs down on their pain med and lawyers began to pitch a class action suit claiming the company had actively misled investors for 2 years about the biotech’s discussions with regulators.